Hundreds of adults and teenagers in England with a rare, inherited eye disease will benefit from a new treatment after NICE today recommended idebenone for visual impairment caused by Leber's ...

NICE and the Medicines and Healthcare products Regulatory Agency (MHRA) have described how the 10-Year Health Plan will lead to faster medicines access for patients in the NHS in England.

The treatment combines pembrolizumab, made by Merck Sharp & Dohme, with chemotherapy drugs carboplatin and paclitaxel. Pembrolizumab is an immunotherapy that helps the immune system recognise and ...

After four years of transformational leadership, NICE CEO Dr Sam Roberts will step down at the end of the year to support her children through a difficult time.

COVID-19 All NICE products on COVID-19. Includes any guidance and advice. Published products on this topic (13) ...

Evidence-based recommendations on olaparib (Lynparza) for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line ...

Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy Technology appraisal ...

Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency Technology appraisal guidance ...

This guideline covers general principles for prescribing and managing withdrawal from opioids, benzodiazepines, gabapentinoids, Z‑drugs and antidepressants in primary and secondary care. It does not ...

This guideline covers diagnosing and managing non-small-cell and small-cell lung cancer. It aims to improve outcomes for patients by ensuring that the most effective tests and treatments are used, and ...

This guideline sets out an antimicrobial prescribing strategy for adults, young people and children aged 72 hours and over with impetigo. It aims to optimise antibiotic use and reduce antibiotic ...

Evidence-based recommendations on dabrafenib (Tafinlar) plus trametinib (Mekinist) for BRAF V600 mutation-positive advanced non-small-cell lung cancer in adults. Commercial arrangement There is a ...